24/7 Market News Snapshot 24 June, 2025 – Klotho Neurosciences, Inc. Common Stock (NASDAQ:KLTO)

June 24, 2025

DENVER, Colo., 24 June, 2025 (www.247marketnews.com) – (NASDAQ:KLTO) are discussed in this article.
Klotho Neurosciences, Inc. (NASDAQ:KLTO) has recently captured significant market attention, reflected in its remarkable premarket performance, with stock trading at $1.465—marking a 22.08% increase from the previous day’s close. The trading volume has soared to 1.33 million shares, further highlighting the growing investor enthusiasm surrounding the company.

In a pivotal move to advance its mission of developing innovative treatments for neurological disorders, Klotho has announced a strategic research collaboration with the Okinawa Research Center for Longevity Science (ORCLS). This partnership seeks to investigate the potential of the human alpha-Klotho gene, a focus of extensive research in longevity, to mitigate neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s.

Located in Okinawa, a region distinguished as a “Blue Zone” with a high proportion of centenarians, ORCLS provides a unique backdrop for this collaboration. The center boasts nearly fifty years of thorough research on the mechanisms of aging and healthy longevity. Preliminary findings suggest that the secreted alpha-Klotho protein (s-KL) may be instrumental in enhancing healthspan and lifespan, with studies indicating a direct relationship between s-KL levels and age-related conditions.

Dr. Joseph Sinkule, CEO of Klotho Neurosciences, underscored the importance of this collaboration, noting the compelling nature of the initial data from ORCLS. He stated that exploring gene therapy aimed at replenishing s-KL levels could potentially open new avenues for protection against degenerative disorders and contribute to healthier aging. Dr. Bradley Willcox of ORCLS echoed this sentiment, referencing the extensive research conducted on centenarians as a basis for further investigation into the implications of Klotho proteins on health outcomes.

By merging cutting-edge biogenetics with decades of longevity research, Klotho Neurosciences is positioning itself to transform treatment strategies for neurodegenerative disorders, ultimately striving to enhance quality of life as populations age.

Related news for (KLTO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.